These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

861 related items for PubMed ID: 20955443

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP, MEDAL Steering Committee.
    Lancet; 2007 Feb 10; 369(9560):465-73. PubMed ID: 17292766
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
    Hsiang KW, Chen TS, Lin HY, Luo JC, Lu CL, Lin HC, Lee KC, Chang FY, Lee SD.
    Clin Ther; 2010 Jul 10; 32(7):1294-303. PubMed ID: 20678677
    [Abstract] [Full Text] [Related]

  • 5. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L, MEDAL Steering Committee.
    Lancet; 2006 Nov 18; 368(9549):1771-81. PubMed ID: 17113426
    [Abstract] [Full Text] [Related]

  • 6. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B.
    Am J Gastroenterol; 2003 Aug 18; 98(8):1725-33. PubMed ID: 12907325
    [Abstract] [Full Text] [Related]

  • 7. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T, Wongbunnak R, Patcharatrakul T, Ratansumawong K, Poigampetch Y, Songpatanasilp T.
    J Med Assoc Thai; 2009 Dec 18; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.
    Baraf HS, Fuentealba C, Greenwald M, Brzezicki J, O'Brien K, Soffer B, Polis A, Bird S, Kaur A, Curtis SP, EDGE Study Group.
    J Rheumatol; 2007 Feb 18; 34(2):408-20. PubMed ID: 17304660
    [Abstract] [Full Text] [Related]

  • 13. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
    Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu Q, Bombardier C.
    Gastroenterology; 2003 Feb 18; 124(2):288-92. PubMed ID: 12557133
    [Abstract] [Full Text] [Related]

  • 14. The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.
    Arber N, Lieberman D, Wang TC, Zhang R, Sands GH, Bertagnolli MM, Hawk ET, Eagle C, Coindreau J, Zauber A, Lanas A, Levin B.
    Clin Ther; 2012 Mar 18; 34(3):569-79. PubMed ID: 22386831
    [Abstract] [Full Text] [Related]

  • 15. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
    Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL.
    Lancet; 2010 Jul 17; 376(9736):173-9. PubMed ID: 20638563
    [Abstract] [Full Text] [Related]

  • 16. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis.
    Ramey DR, Watson DJ, Yu C, Bolognese JA, Curtis SP, Reicin AS.
    Curr Med Res Opin; 2005 May 17; 21(5):715-22. PubMed ID: 15974563
    [Abstract] [Full Text] [Related]

  • 17. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
    Cannon CP, Curtis SP, Bolognese JA, Laine L, MEDAL Steering Committee.
    Am Heart J; 2006 Aug 17; 152(2):237-45. PubMed ID: 16875903
    [Abstract] [Full Text] [Related]

  • 18. Global gastrointestinal safety profile of etoricoxib and lumiracoxib.
    Yuan Y, Hunt RH.
    Curr Pharm Des; 2007 Aug 17; 13(22):2237-47. PubMed ID: 17691997
    [Abstract] [Full Text] [Related]

  • 19. The effect of low-dose aspirin on the decreased risk of development of dyspepsia and gastrointestinal ulcers associated to cyclooxygenase-2 selective inhibitors.
    Benito-Garcia E, Michaud K, Wolfe F.
    J Rheumatol; 2007 Aug 17; 34(8):1765-9. PubMed ID: 17611980
    [Abstract] [Full Text] [Related]

  • 20. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
    Laine L, Goldkind L, Curtis SP, Connors LG, Yanqiong Z, Cannon CP.
    Am J Gastroenterol; 2009 Feb 17; 104(2):356-62. PubMed ID: 19174782
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.